INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
August 01 2019 - 9:01AM
INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, today announced that RJ Tesi, M.D.,
co-founder and CEO, will present at the Cambridge Healthcare
Institute’s 7th Annual Immuno-Oncology Summit, taking place in
Boston from Aug. 5 through Aug. 9.
“We are committed to helping treatment-resistant
patients by advancing the clinical development of combination
therapies and other effective cancer treatments,” said Dr. Tesi. “I
am delighted to have the chance to present with some of the most
prominent leaders in the immuno-oncology community.”
Below is a schedule of Dr. Tesi’s presentations at the
conference:
Monday, August 5 at 9:00 a.m.“Targeting
Soluble TNF to Improve Efficacy of Combination
Immunotherapy” Dr. Tesi will delve into how a fast-growing
patient population in cancer is resistant to checkpoint inhibitors
(CPI) and how combination therapy is starting to become a standard
in immunotherapy by combining drugs with different targets.
Tuesday, August 6 at 4:15 p.m.
“Next-Generation Immunotherapies” Dr. Tesi will
participate on a panel alongside notable company spokespeople,
covering the latest advances in immunotherapy, technology and
implementation strategies for next-generation immunotherapies.
Thursday, August 8 at 4:15
p.m.“Targeting ‘Protector’ Cells of the Innate
Immune System”Dr. Tesi will address the complex
immunobiology of how cancer destroys the patient’s immune cells as
protection from immunotherapy. He will discuss strategies to
eliminating protector cells that alter the immunologic balance in
favor of tumor eradication.
Cambridge Healthcare Institute’s 7th Annual
Immuno-Oncology Summit brings together leaders from across the
immunotherapy industry and provides a unique opportunity to network
with decision-makers, build lasting collaborations and gain
actionable solutions. The conference presents a unique chance to
connect scientists on immunology-related drug targets to address
the latest discoveries in the field.
About INmune Bio, Inc.INmune Bio, Inc. is a
publicly traded (NASDAQ: INMB) clinical-stage biotechnology company
developing therapies targeting the innate immune system to fight
disease. INmune Bio is developing three product platforms: two
products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that
is currently focused on Alzheimer’s disease. INKmune is a natural
killer (NK) cell therapeutic that primes the patient’s NK cells to
attack minimal residual disease, the remaining cancer cells that
are difficult to detect, which often cause relapse. INB03 inhibits
myeloid-derived suppressor cells (MDSC), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes
microglial activation and neuronal cell death. INmune Bio’s product
platforms utilize a precision medicine approach for the treatment
of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit
www.inmunebio.com.
INmune Bio Contact: David Moss, CFO(858)
964-3720DMoss@INmuneBio.com
Media Contact: Antenna GroupHolly Dugan(201)
465-8019INmuneBio@AntennaGroup.com
Investor Contact: KCSA Strategic
Communications Valter Pinto / Scott Eckstein PH: (212)
896-1254 / (212) 896-1210INmune@KCSA.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2023 to Aug 2024